AliveCor announced today that it received FDA clearance for the next generation of its AI technology for the Kardia 12L ECG ...

HeartBeam (NASDAQ: BEAT) was among the medical device companies highlighted in a Jan. 8 report by Modern Healthcare by Lauren ...

AccurECG is AccurKardia's FDA-cleared Class II software as a medical device (SaMD) platform for fully automated, near real-time ECG interpretation. AccurECG provides beat-by-beat analysis, ventricular ...

Austin, Texas, United States, January 5th, 2026, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...

Abstract: With the popularization of computer technology and the development of signal processing technology, the computer automatic diagnosis of ECG has entered the practical stage. In this paper, a ...

Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (HSCS) (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information ...

Heartbeam Inc. company and executive profile by Barron's. View the latest BEAT company infomation and executive bios.

HeartBeam’s ECG software duplicates the 12-lead ECG approach undertaken in healthcare settings with electrodes to evaluate heart arrhythmias.

SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ:BEAT) announced Wednesday that the U.S. Food and Drug Administration has granted 510 (k) clearance for its 12-lead electrocardiogram (ECG) synthesis ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for ...